Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Roziakova, Lubica ^a,b   Bojtarova, Eva ^b   Mistrik, Martin ^b   Dubrava, Juraj ^b   Gergel, Jozef ^c   Lenkova, Nadezda ^c   Mladosievicova, Beata ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^c University Hospital Bratislava ^*  (Slovakia)

Author keywords

Cardiac troponins; Cardiotoxicity; Hematopoietic stem cell transplantation; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMSACRINE; ANTHRACYCLINE DERIVATIVE; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MELPHALAN; MITOXANTRONE; THYMOCYTE ANTIBODY; TROPONIN T; ANTHRACYCLINE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOGENIC SHOCK; CARDIOTOXICITY; CLINICAL ARTICLE; DIASTOLE; DRUG EFFECT; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FLUID RETENTION; HEART MUSCLE INJURY; HEMATOLOGIC DISEASE; HUMAN; MALE; PERICARDITIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; SIDE EFFECT; SYSTOLE; THORAX PAIN; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BEHAVIOR THERAPY; BLOOD; FOLLOW UP; HEART MUSCLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; METHODOLOGY; PATHOLOGY;

ADULT; ANTHRACYCLINES; BEHAVIOR THERAPY; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TRANSPLANTATION, HOMOLOGOUS; TROPONIN T;

EID: 84856797420     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-13     Document Type: Article

References (25)

1. Stem cells in clinical practice: applications and warnings. Lodi D, Iannitti T, Palmieri B, J Exp Clin Cancer Res 2011 30 9 10.1186/1756-9966-30-9 21241480
2. Late mortality after hematopietic stem cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, McGlave PB, Nademanee A, O'Donnell M, Ramsay NK, Robison LL, Snyder D, Stein A, Forman SJ, Weisdorf DJ, Blood 2007 110 3784 3791 10.1182/blood-2007-03-082933 17671231 (Pubitemid 350159650)
3. How I treat late effects in adults after allogeneic stem cell transplantation. Savani BN, Griffith ML, Jagasia S, Lee SJ, Blood 2011 117 11 3002 3009 10.1182/blood-2010-10-263095 21193694
4. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S, Blood 2010 116 17 3129 3139 10.1182/blood-2009-06-229369 20656930
5. Role of biomarkers in chemotherapy-induced cardiotoxicity. Cardinale D, Sandri MM, Prog Cardiovasc Dis 2010 53 2 121 129 10.1016/j.pcad.2010.04.002 20728699
6. Transplantation vs conventional-dose therapy for amyloidosis. Palladini G, Merlini G, Curr Opin Oncol 2011 23 2 214 220 10.1097/CCO.0b013e328342b840 21178616
7. Cardiac assessment of patients for haematopoietic stem cell transplantation. Coghlan JG, Handler CE, Kottaridis PD, Best Pract Res Clin Haematol 2007 20 247 263 10.1016/j.beha.2006.09.005 17448960 (Pubitemid 46591152)
8. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX, Ferrans VJ, J Clin Oncol 1999 17 7 2237 2243 10561281 (Pubitemid 29318858)
9. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M, Eur Heart J 2006 27 330 337 16293638 (Pubitemid 43100029)
10. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, Hart DN, Bone Marrow Transplant 2000 26 309 313 10.1038/sj.bmt.1702507 10967571 (Pubitemid 30614412)
11. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Niwa N, Watanabe E, Hamaguchi M, Kodera Y, Miyazaki H, Kodama I, Ohono M, Ann Hematol 2001 80 460 465 10.1007/s002770100331 11563591 (Pubitemid 32771608)
12. Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Masuko M, Ito M, Kurasaki T, Yano T, Takizawa J, Toba K, Aoki S, Fuse I, Kodama M, Furukawa T, Aizawa Y, Intern Med 2007 46 551 555 10.2169/internalmedicine.46.6188 17473487 (Pubitemid 46845844)
13. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Horacek JM, Pudil R, Tichy M, Jebavy L, Zak P, Slovacek L, Maly J, Exp Oncol 2007 29 343 347
14. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM, Clin Chem 2005 51 1405 1410 10.1373/clinchem.2005.050153 15932966 (Pubitemid 41060872)
15. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Rr P, Libby P, Clin Chem 2008 54 24 38 18160725 (Pubitemid 351182593)
16. The role of IL-1 in the pathogenesis of heart disease. Bujak M, Frangogiannis NG, Arch Immunol Ther Exp (Warsz) 2009 57 165 176 10.1007/s00005-009-0024-y
17. Biomarkers: even low cTnT levels are indicative of structural heart disease and might be useful in screening. Mearns BM, Nat Rev Cardiol 2011 8 2 61 10.1038/nrcardio.2010.211 21348137
18. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK, JAMA 2010 304 22 2503 2512 10.1001/jama.2010.1768 21139111
19. Cardiovascular toxicity of antitumor drugs: dimensions of the problem in children. Schully R, Lipschultz SE, Cardiotoxicity of non-cardiovascular drugs, Minotti G, Wiley, 2010 97 126
20. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Auner HW, Tinchon C, Brezinschek RI, Eibl M, Sormann S, Maizen C, Linkesch W, Schmon-Kampel R, Quehenberger F, Tiran A, Sill H, Eur J Haematol 2002 69 1 6 10.1034/j.1600-0609.2002.01661.x 12270055 (Pubitemid 35155433)
21. Multimarker approach to evaluation of cardiac toxicity during preparative regimen and hematopoietic cell transplantation. Horacek JM, Tichy M, Pudil R, Jebavy L, Zak P, Ulrychova M, Slovacek L, Maly J, Neoplasma 2008 55 532 537 18999883
22. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Peres E, Levine JE, Khaled YA, Ibrahim RB, Braun TM, Krijanovski OI, Mineishi S, Abidi MH, Bone Marrow Transplant 2010 45 149 151 10.1038/bmt.2009.97 19465940
23. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Kremer L, Van Der Pal HJ, Offringa M, Van Dalen EC, Vote PA, Ann Oncol 2002 13 819 829 10.1093/annonc/mdf167 12123328 (Pubitemid 34752678)
24. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H, Ann Hematol 2003 82 218 221 12679885
25. CTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, Celik I, Kes S, Tekuzman G, Ann Oncol 2005 16 798 804 10.1093/annonc/mdi152 15774486 (Pubitemid 40767103)